A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.

ABSTRACT:

Objectives

To perform a Bayesian reanalysis of a recent trial of psilocybin (COMP360) versus escitalopram for Major Depressive Disorder (MDD) in order to provide a more informative interpretation of the indeterminate outcome of a previous frequentist analysis.

Design

Reanalysis of a two-arm double-blind placebo controlled trial.

Participants

Fifty-nine patients with MDD.

Interventions

Two doses of psilocybin 25mg and daily oral placebo versus daily escitalopram and 2 doses of psilocybin 1mg, with psychological support for both groups.

Outcome measures

Quick Inventory of Depressive Symptomatology-Self-Report (QIDS SR-16), and three other depression scales as secondary outcomes: HAMD-17, MADRS, and BDI-1A.

Results

Using Bayes factors and 'skeptical

SUBMITTER: Nayak SM 

PROVIDER: S-EPMC10278160 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature